EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer
In order to identify anaplastic lymphoma kinase-driven non-small cell lung cancer (ALK+ NSCLC) patients with a worse outcome, who might require alternative therapeutic approaches, we retrospectively analyzed all stage IV cases treated at our institutions with one of the main echinoderm microtubule-a...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[15 June 2018]
|
| In: |
International journal of cancer
Year: 2018, Jahrgang: 142, Heft: 12, Pages: 2589-2598 |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.31275 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1002/ijc.31275 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.31275 
|
| Verfasserangaben: | Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr, Mei Elsayed, Martina Kirchner, Jonas Ristau, Ivo Buchhalter, Roland Penzel, Felix J. Herth, Claus P. Heussel, Martin Eichhorn, Thomas Muley, Michael Meister, Jürgen R. Fischer, Stefan Rieken, Arne Warth, Helge Bischoff, Peter Schirmacher, Albrecht Stenzinger, Michael Thomas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1665454989 | ||
| 003 | DE-627 | ||
| 005 | 20230426084909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190514s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijc.31275 |2 doi | |
| 035 | |a (DE-627)1665454989 | ||
| 035 | |a (DE-599)KXP1665454989 | ||
| 035 | |a (OCoLC)1341212893 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Christopoulos, Petros |d 1977- |e VerfasserIn |0 (DE-588)138659702 |0 (DE-627)604886756 |0 (DE-576)308488067 |4 aut | |
| 245 | 1 | 0 | |a EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer |c Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr, Mei Elsayed, Martina Kirchner, Jonas Ristau, Ivo Buchhalter, Roland Penzel, Felix J. Herth, Claus P. Heussel, Martin Eichhorn, Thomas Muley, Michael Meister, Jürgen R. Fischer, Stefan Rieken, Arne Warth, Helge Bischoff, Peter Schirmacher, Albrecht Stenzinger, Michael Thomas |
| 264 | 1 | |c [15 June 2018] | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published: 24 January 2018 | ||
| 500 | |a Gesehen am 14.05.2019 | ||
| 520 | |a In order to identify anaplastic lymphoma kinase-driven non-small cell lung cancer (ALK+ NSCLC) patients with a worse outcome, who might require alternative therapeutic approaches, we retrospectively analyzed all stage IV cases treated at our institutions with one of the main echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion variants V1, V2 and V3 as detected by next-generation sequencing or reverse transcription-polymerase chain reaction (n = 67). Progression under tyrosine kinase inhibitor (TKI) treatment was evaluated both according to Response Evaluation Criteria in Solid Tumors (RECIST) and by the need to change systemic therapy. EML4-ALK fusion variants V1, V2 and V3 were found in 39%, 10% and 51% of cases, respectively. Patients with V3-driven tumors had more metastatic sites at diagnosis than cases with the V1 and V2 variants (mean 3.3 vs. 1.9 and 1.6, p = 0.005), which suggests increased disease aggressiveness. Furthermore, V3-positive status was associated with earlier failure after treatment with first and second-generation ALK TKI (median progression-free survival [PFS] by RECIST in the first line 7.3 vs. 39.3 months, p = 0.01), platinum-based combination chemotherapy (median PFS 5.4 vs. 15.2 months for the first line, p = 0.008) and cerebral radiotherapy (median brain PFS 6.1 months vs. not reached for cerebral radiotherapy during first-line treatment, p = 0.028), and with inferior overall survival (39.8 vs. 59.6 months in median, p = 0.017). Thus, EML4-ALK fusion variant V3 is a high-risk feature for ALK+ NSCLC. Determination of V3 status should be considered as part of the initial workup for this entity in order to select patients for more aggressive surveillance and treatment strategies. | ||
| 650 | 4 | |a ALK+ NSCLC | |
| 650 | 4 | |a EML4-ALK fusion variant | |
| 650 | 4 | |a metastasis | |
| 650 | 4 | |a survival | |
| 650 | 4 | |a treatment failure | |
| 700 | 1 | |a Endris, Volker |e VerfasserIn |0 (DE-588)1063753686 |0 (DE-627)812590961 |0 (DE-576)422898198 |4 aut | |
| 700 | 1 | |a Bozorgmehr, Farastuk |d 1979- |e VerfasserIn |0 (DE-588)141921811 |0 (DE-627)632526734 |0 (DE-576)326848150 |4 aut | |
| 700 | 1 | |a El Sayed, Mei |e VerfasserIn |0 (DE-588)1185583343 |0 (DE-627)1664958355 |4 aut | |
| 700 | 1 | |a Kirchner, Martina |d 1973- |e VerfasserIn |0 (DE-588)1017178976 |0 (DE-627)676266363 |0 (DE-576)353239747 |4 aut | |
| 700 | 1 | |a Ristau, Jonas |d 1989- |e VerfasserIn |0 (DE-588)1075216303 |0 (DE-627)83302986X |0 (DE-576)443326444 |4 aut | |
| 700 | 1 | |a Buchhalter, Ivo |e VerfasserIn |0 (DE-588)1137856548 |0 (DE-627)895131471 |0 (DE-576)491773684 |4 aut | |
| 700 | 1 | |a Penzel, Roland |e VerfasserIn |0 (DE-588)102044021X |0 (DE-627)691221316 |0 (DE-576)360421083 |4 aut | |
| 700 | 1 | |a Herth, Felix |e VerfasserIn |0 (DE-588)1016095236 |0 (DE-627)705477568 |0 (DE-576)351509925 |4 aut | |
| 700 | 1 | |a Heußel, Claus Peter |e VerfasserIn |0 (DE-588)1048631389 |0 (DE-627)780769422 |0 (DE-576)40288146X |4 aut | |
| 700 | 1 | |a Eichhorn, Martin E. |d 1974- |e VerfasserIn |0 (DE-588)124436900 |0 (DE-627)363346627 |0 (DE-576)294170545 |4 aut | |
| 700 | 1 | |a Muley, Thomas |e VerfasserIn |0 (DE-588)1056885432 |0 (DE-627)794179169 |0 (DE-576)16759284X |4 aut | |
| 700 | 1 | |a Meister, Michael |e VerfasserIn |0 (DE-588)1078792046 |0 (DE-627)839461402 |0 (DE-576)451890108 |4 aut | |
| 700 | 1 | |a Rieken, Stefan |d 1979- |e VerfasserIn |0 (DE-588)135553385 |0 (DE-627)567062570 |0 (DE-576)278641725 |4 aut | |
| 700 | 1 | |a Warth, Arne |d 1979- |e VerfasserIn |0 (DE-588)132646145 |0 (DE-627)524716927 |0 (DE-576)260019755 |4 aut | |
| 700 | 1 | |a Bischoff, Helge |d 1958- |e VerfasserIn |0 (DE-588)111184576 |0 (DE-627)389658286 |0 (DE-576)167287249 |4 aut | |
| 700 | 1 | |a Schirmacher, Peter |d 1961- |e VerfasserIn |0 (DE-588)1020440112 |0 (DE-627)691221197 |0 (DE-576)360427448 |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e VerfasserIn |0 (DE-588)139606106 |0 (DE-627)703395238 |0 (DE-576)312432755 |4 aut | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d Bognor Regis : Wiley-Liss, 1966 |g 142(2018), 12, Seite 2589-2598 |h Online-Ressource |w (DE-627)269532781 |w (DE-600)1474822-8 |w (DE-576)079876129 |x 1097-0215 |7 nnas |a EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer |
| 773 | 1 | 8 | |g volume:142 |g year:2018 |g number:12 |g pages:2589-2598 |g extent:10 |a EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1002/ijc.31275 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.31275 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190514 | ||
| 992 | |a 20190514 | ||
| 993 | |a Article | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 994 | |a 2018 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 20 |y j | ||
| 998 | |g 139606106 |a Stenzinger, Albrecht |m 139606106:Stenzinger, Albrecht |d 910000 |d 912000 |e 910000PS139606106 |e 912000PS139606106 |k 0/910000/ |k 1/910000/912000/ |p 19 | ||
| 998 | |g 1020440112 |a Schirmacher, Peter |m 1020440112:Schirmacher, Peter |d 910000 |d 912000 |e 910000PS1020440112 |e 912000PS1020440112 |k 0/910000/ |k 1/910000/912000/ |p 18 | ||
| 998 | |g 111184576 |a Bischoff, Helge |m 111184576:Bischoff, Helge |d 910000 |d 950000 |d 950900 |e 910000PB111184576 |e 950000PB111184576 |e 950900PB111184576 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 17 | ||
| 998 | |g 132646145 |a Warth, Arne |m 132646145:Warth, Arne |d 910000 |d 912000 |e 910000PW132646145 |e 912000PW132646145 |k 0/910000/ |k 1/910000/912000/ |p 16 | ||
| 998 | |g 135553385 |a Rieken, Stefan |m 135553385:Rieken, Stefan |d 910000 |d 911400 |e 910000PR135553385 |e 911400PR135553385 |k 0/910000/ |k 1/910000/911400/ |p 15 | ||
| 998 | |g 1078792046 |a Meister, Michael |m 1078792046:Meister, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PM1078792046 |e 950000PM1078792046 |e 950900PM1078792046 |e 50000PM1078792046 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 13 | ||
| 998 | |g 1056885432 |a Muley, Thomas |m 1056885432:Muley, Thomas |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PM1056885432 |e 950000PM1056885432 |e 950900PM1056885432 |e 50000PM1056885432 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 12 | ||
| 998 | |g 124436900 |a Eichhorn, Martin E. |m 124436900:Eichhorn, Martin E. |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PE124436900 |e 950000PE124436900 |e 950900PE124436900 |e 50000PE124436900 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 11 | ||
| 998 | |g 1048631389 |a Heußel, Claus Peter |m 1048631389:Heußel, Claus Peter |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PH1048631389 |e 950000PH1048631389 |e 950900PH1048631389 |e 50000PH1048631389 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 10 | ||
| 998 | |g 1016095236 |a Herth, Felix |m 1016095236:Herth, Felix |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PH1016095236 |e 950000PH1016095236 |e 950900PH1016095236 |e 50000PH1016095236 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 9 | ||
| 998 | |g 102044021X |a Penzel, Roland |m 102044021X:Penzel, Roland |d 910000 |d 912000 |e 910000PP102044021X |e 912000PP102044021X |k 0/910000/ |k 1/910000/912000/ |p 8 | ||
| 998 | |g 1137856548 |a Buchhalter, Ivo |m 1137856548:Buchhalter, Ivo |p 7 | ||
| 998 | |g 1075216303 |a Ristau, Jonas |m 1075216303:Ristau, Jonas |d 910000 |d 911400 |e 910000PR1075216303 |e 911400PR1075216303 |k 0/910000/ |k 1/910000/911400/ |p 6 | ||
| 998 | |g 1017178976 |a Kirchner, Martina |m 1017178976:Kirchner, Martina |d 50000 |e 50000PK1017178976 |k 0/50000/ |p 5 | ||
| 998 | |g 1185583343 |a El Sayed, Mei |m 1185583343:El Sayed, Mei |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PE1185583343 |e 950000PE1185583343 |e 950900PE1185583343 |e 50000PE1185583343 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 4 | ||
| 998 | |g 141921811 |a Bozorgmehr, Farastuk |m 141921811:Bozorgmehr, Farastuk |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PB141921811 |e 950000PB141921811 |e 950900PB141921811 |e 50000PB141921811 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 3 | ||
| 998 | |g 1063753686 |a Endris, Volker |m 1063753686:Endris, Volker |d 910000 |d 912000 |e 910000PE1063753686 |e 912000PE1063753686 |k 0/910000/ |k 1/910000/912000/ |p 2 | ||
| 998 | |g 138659702 |a Christopoulos, Petros |m 138659702:Christopoulos, Petros |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PC138659702 |e 950000PC138659702 |e 950900PC138659702 |e 50000PC138659702 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1665454989 |e 3475790653 | ||
| 999 | |a KXP-PPN1665454989 |e 3475770180 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1665454989","physDesc":[{"extent":"10 S."}],"relHost":[{"id":{"zdb":["1474822-8"],"doi":["10.1002/(ISSN)1097-0215"],"issn":["1097-0215"],"eki":["269532781"]},"part":{"pages":"2589-2598","year":"2018","text":"142(2018), 12, Seite 2589-2598","extent":"10","volume":"142","issue":"12"},"origin":[{"dateIssuedDisp":"1966-","dateIssuedKey":"1966","publisherPlace":"Bognor Regis","publisher":"Wiley-Liss"}],"title":[{"subtitle":"publication of the International Union against Cancer (UICC) = Journal international du cancer","title":"International journal of cancer","title_sort":"International journal of cancer"}],"disp":"EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancerInternational journal of cancer","titleTranslated":[{"translated":"Journal international du cancer"}],"pubHistory":["1.1966 -"],"language":["eng"],"titleAlt":[{"title":"Predictive oncology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"269532781","corporate":[{"display":"International Union against Cancer","role":"isb"}],"note":["Gesehen am 28.02.08","Darin: Predictive oncology"]}],"note":["First published: 24 January 2018","Gesehen am 14.05.2019"],"language":["eng"],"origin":[{"dateIssuedDisp":"[15 June 2018]","dateIssuedKey":"2018"}],"person":[{"role":"aut","display":"Christopoulos, Petros","family":"Christopoulos","given":"Petros"},{"given":"Volker","family":"Endris","display":"Endris, Volker","role":"aut"},{"display":"Bozorgmehr, Farastuk","role":"aut","family":"Bozorgmehr","given":"Farastuk"},{"given":"Mei","family":"El Sayed","display":"El Sayed, Mei","role":"aut"},{"family":"Kirchner","display":"Kirchner, Martina","role":"aut","given":"Martina"},{"family":"Ristau","display":"Ristau, Jonas","role":"aut","given":"Jonas"},{"family":"Buchhalter","display":"Buchhalter, Ivo","role":"aut","given":"Ivo"},{"given":"Roland","display":"Penzel, Roland","role":"aut","family":"Penzel"},{"given":"Felix","family":"Herth","display":"Herth, Felix","role":"aut"},{"given":"Claus Peter","family":"Heußel","role":"aut","display":"Heußel, Claus Peter"},{"role":"aut","display":"Eichhorn, Martin E.","family":"Eichhorn","given":"Martin E."},{"family":"Muley","display":"Muley, Thomas","role":"aut","given":"Thomas"},{"role":"aut","display":"Meister, Michael","family":"Meister","given":"Michael"},{"family":"Rieken","role":"aut","display":"Rieken, Stefan","given":"Stefan"},{"given":"Arne","family":"Warth","role":"aut","display":"Warth, Arne"},{"given":"Helge","display":"Bischoff, Helge","role":"aut","family":"Bischoff"},{"given":"Peter","family":"Schirmacher","display":"Schirmacher, Peter","role":"aut"},{"family":"Stenzinger","role":"aut","display":"Stenzinger, Albrecht","given":"Albrecht"},{"role":"aut","display":"Thomas, Michael","family":"Thomas","given":"Michael"}],"id":{"eki":["1665454989"],"doi":["10.1002/ijc.31275"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer","title":"EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer"}],"name":{"displayForm":["Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr, Mei Elsayed, Martina Kirchner, Jonas Ristau, Ivo Buchhalter, Roland Penzel, Felix J. Herth, Claus P. Heussel, Martin Eichhorn, Thomas Muley, Michael Meister, Jürgen R. Fischer, Stefan Rieken, Arne Warth, Helge Bischoff, Peter Schirmacher, Albrecht Stenzinger, Michael Thomas"]}} | ||
| SRT | |a CHRISTOPOUEML4ALKFUS1520 | ||